The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Items 301–400 of 678
González, P., Álvarez, V., Menéndez‐González, M., Lahoz, C., Martínez, C., Corao, A. I., Calatayud, M. T. R., Peña, J., García-Castro, M., & Coto, E. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.055 · Cited by 26
Cell competition from development to neurodegeneration
RODRIGUES, M. C., Couceiro, J., & Moreno, E. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048926 · Cited by 24
Single-cell Transcriptional Changes in Neurodegenerative Diseases
Ahmadi, A., Gispert, J. D., Navarro, A., Vilor‐Tejedor, N., & Sadeghi, I. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.025 · Cited by 22
“Patients with C9orf72 hexanucleotide repeat expansions have accumulations of dipeptide repeat proteins which are translated from the GGGGCC repeats, although this repeat is located in a non-coding region of the gene (Bertram and Tanzi, 2005).”
Class A and C GPCR Dimers in Neurodegenerative Diseases
Moreira, I. S., Caniceiro, A. B., Bueschbell, B., & Schiedel, A. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327221830 · Cited by 21
Papadopoulos, N., Suelves, N., Perrin, F., Vadukul, D. M., Vrancx, C., Constantinescu, S. N., & Kienlen-Campard, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112753 · Cited by 20
“For example, gene mutations have been linked to the onset of inherited forms of AD [10] and it has been proven that they can affect the conformational dynamics of Aβ.”
BackgroundModeling brain dynamics using computational neurogenetic approach
Beňušková, Ľ., & Kasabov, N. K. (2008) · Cognitive Neurodynamics · doi:10.1007/s11571-008-9061-1 · Cited by 24
“APP gene (early-onset AD)/21q21 APOE-e4 (lateonset AD)/19q13 Plaques made of fragmented brain cells surrounded by amyloid-family proteins, tangles of cytoskeleton filaments Progressive inability to remember facts and events and, later, to recognize friends and family Citron 2004; Pastor and Goate 2004; Bertram and Tan…”
BackgroundGattoni, G., & Bernocchi, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092364 · Cited by 21
“In this context, we find it of particular interest to compare these results with a pathological condition such as Alzheimer’s disease (AD), which is the most widespread and costly neurodegenerative disease in the world, accounting for more than 50% cases of dementia [190].”
ResultAssociations between VHL genotype and clinical phenotype in familial von Hippel–Lindau disease
Huang, J.-S., Huang, C., Chen, S. K., Chien, C., Chen, C. W., & Lin, C. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01806.x · Cited by 21
Fernandez, L. L., Carmona, M., Portero‐Otín, M., Naudí, A., Pamplona, R., Schröder, N., & Ferrer, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1304 · Cited by 23
“Familial AD is a very rare autosomal dominant disease, often with early onset, caused by mutations in the amyloid-β protein precursor and presenilin genes (AβPP, PSEN1, PSEN2) both linked to Aβ metabolism [3–5].”
BackgroundThe LDLR locus in alzheimer's disease: A family-based study and meta-analysis of case-control data
Bertram, L., Hsiao, M., McQueen, M. B., Parkinson, M., Mullin, K., Blacker, D., & Tanzi, R. E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.11.005 · Cited by 20
Self-citationPharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer’s disease: a meta-analysis
Yang, R., Duan, J., Luo, F., Tao, P., & Hu, C. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01369-4 · Cited by 20
Analysis of ALS-related proteins during herpes simplex virus-2 latent infection
Cabrera, J. R., Rodríguez‐Izquierdo, I., Jiménez, J. L., & Muñoz‐Fernández, M. Á. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02044-4 · Cited by 20
“In a limited number of cases, the unique cause of the NDD is a genetic alteration, however, the majority of NDDs cases are idiopathic [1, 2].”
BackgroundJones, M., Wang, J., Harmon, S., Kling, B., Heilmann, J., & Gilmer, J. F. (2016) · Molecules · doi:10.3390/molecules21040440 · Cited by 20
“Alzheimer’s disease (AD) is now the most common neurodegenerative disease, with more than 20 million cases worldwide [1].”
Neurodegeneration in tauopathies and synucleinopathies
Foguem, C., & Kamsu-Foguem, B. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2016.05.002 · Cited by 20
Erekat, N. S., & Al-Jarrah, M. D. (2018) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.910307 · Cited by 19
MicroRNA-138 Overexpression Alters Aβ42 Levels and Behavior in Wildtype Mice
Boscher, E., Goupil, C., Petry, S., Keraudren, R., Loiselle, A., Planel, E., & Hébert, S. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.591138 · Cited by 24
“However, only autosomal dominant mutations in APP, PSEN1, or PSEN2 genes are identified as causal in a small fraction of EOAD cases (1%–5%) (Campion et al., 1999; Bertram and Tanzi, 2005).”
BackgroundGuard of Delinquency? A Role of Microglia in Inflammatory Neurodegenerative Diseases of the CNS
Wu, W., Shao, J., Lu, H., Xu, J., Zhu, A., Fang, W., & Hui, G. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-9872-0 · Cited by 21
“It is thought that nutritional deficiencies, environmental toxins, heavy metals, chronic bacterial and viral infections, autoimmune immunological responses, vascular diseases, head trauma, and accumulation of fluid in the brain, changes in neurotransmitter concentrations are involved in the pathogenesis of various neu…”
BackgroundIntranasal Delivery of Chitosan–siRNA Nanoparticle Formulation to the Brain
Malhotra, M., Tomaro-Duchesneau, C., Saha, S., & Prakash, S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0363-4_15 · Cited by 22
Ye, C., Behnke, J. A., Hardin, K. R., & Zheng, J. Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1150694 · Cited by 24
“While an increasing number of risk genes and mutations have been identified, these genetic factors only account for a small portion of neurodegenerative cases (Bertram and Tanzi, 2005; Hardy and Orr, 2006; Pihlstrøm et al., 2018; Fu and Ip, 2023).”
BackgroundInhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
Hane, F. T., Li, T., Plata, J. A., Hassan, A. A., Granberg, K., & Albert, M. S. (2018) · Diagnostics · doi:10.3390/diagnostics8020041 · Cited by 21
Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease
Ferreira, C., de Almeida, M. C. M. D., Tenreiro, S., & Quintas, A. (2020) · Life · doi:10.3390/life10060086 · Cited by 22
Asthana, P., Zhang, N., Kumar, G., Chine, V. B., Singh, K. K., Mak, Y. L., Chan, L. L., Lam, P. K. S., & Ma, C. H. E. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0875-5 · Cited by 20
“Neurodegenerative diseases are mostly idiopathic in nature with the exception of a few identified possible etiologies and rare familial forms that are still not fully understood [106].”
BackgroundCRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases
Rahman, S., Datta, M., Kim, J., & Jan, A. T. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.014 · Cited by 21
Sankaramourthy, D., Sankaranarayanan, L., Subramanian, K., & Sadras, S. R. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0448 · Cited by 17
Bajaj, S., Zameer, S., Jain, S., Yadav, V., & Vohora, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00699 · Cited by 19
Wang, J., Xu, S., Dai, Y., & Gao, S. (2022) · IEEE Sensors Journal · doi:10.1109/jsen.2022.3223878 · Cited by 21
“In addition, ALS, whose prevalence is as high as about 4.42 people per 100 000 [3], is the most common motor neuron disease [4] and one of the most common neurodegenerative diseases [5] with no effective solutions [6].”
BackgroundInfluentialNeurodegenerative disorders: Dysregulation of a carefully maintained balance?
Swart, C., Haylett, W. L., Kinnear, C. J., Johnson, G., Bardien, S., & Loos, B. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.09.003 · Cited by 23
“This hypothesis is supported by genetic evidence: mutations in the APP, PSEN1 and PSEN2 (encoding β-secretase and γ-secretase, respectively) genes all induce a familial form of AD and increase the deposition of Aβ (Bertram and Tanzi, 2005).”
BackgroundA systems biology-led insight into the role of the proteome in neurodegenerative diseases
Fasano, M., Monti, C., & Alberio, T. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1219254 · Cited by 18
Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases
Subramaniam, N. S., Bawden, C. S., Waldvogel, H. J., Faull, R. L. M., Howarth, G. S., & Snell, R. G. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.017 · Cited by 18
Interaction between Alzheimer's Amyloid-β and Amyloid-β-Metal Complexes with Cell Membranes
Suwalsky, M., Bolognin, S., & Zatta, P. F. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1032 · Cited by 20
“A significant amount of literature is available suggesting that AD is a multifactorial disease [10], and it appears likely that A β is sensitive to many stimula which can cause its shift towards pathogenic pathways [11].”
Li, M., Wang, W., Li, Y., Wang, L., Shen, X., & Tang, Z. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.011 · Cited by 18
Masseroli, M. (2007) · IEEE Transactions on Information Technology in Biomedicine · doi:10.1109/titb.2006.884367 · Cited by 19
“These diseases are the two most widespread progressive neurodegenerative disorders, they have common epidemiological characteristics, and their active study is showing that similar proteins, pathways, and neurotoxic mechanisms can be responsible for their pathogenesis [40], [41].”
BackgroundTargeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases
Longhena, F., Spano, P., & Bellucci, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_60 · Cited by 22
Progression in familial and nonfamilial MS
Koch, M. W., Uyttenboogaart, M., Heerings, M. A. P., Heersema, D. J., Mostert, J. P., & Keyser, J. D. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084269 · Cited by 17
Sleep Disorders in Neurodegenerative Diseases with Dementia: A Comprehensive Review
Siwecka, N., Golberg, M., Świerczewska, D., Filipek, B., Pendrasik, K., Bączek-Grzegorzewska, A., Stasiołek, M., & Matysiak, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197119 · Cited by 20
Krishnan, S., York, M. K., Backus, D. A., & Heyn, P. C. (2017) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2016.11.002 · Cited by 16
“Caring for a person with a neurodegenerative disease (eg, Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington disease) can be extremely challenging.(1) The challenges grow as the disease gets worse.”
BackgroundEngineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 13
“…causes underlying NDs associated with protein aggregation were uncovered, leading to the distinction between rarer familial forms, where disease-causing mutations are genetically inherited, and the more common sporadic forms, where genetic and environmental risk factors drive the pathogenesis [6].”
BackgroundNanotechnology in tissue engineering: expanding possibilities with nanoparticles
Sardari, S., Hheidari, A., Ghodousi, M., Rahi, A., & Pishbin, E. (2024) · Nanotechnology · doi:10.1088/1361-6528/ad5cfb · Cited by 17
“Together, the rising incidence of neurodegenerative disorders and the rapid increase in the average age of the world’s population constitute a major risk to human health that must be taken very seriously [89].”
Atakan, H. B., Cornaglia, M., Mouchiroud, L., Auwerx, J. H., & Gijs, M. A. M. (2019) · Lab on a Chip · doi:10.1039/c8lc00863a · Cited by 21
Breydo, L., Morgan, D., & Uversky, V. N. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9148-8 · Cited by 17
“Characteristics of this disease are the progressive death of the dopaminergic neurons and the presence of protein inclusions, termed Lewy bodies (LBs) and Lewy neurites (LNs), in the surviving neurons [1].”
BackgroundHemminki, K., Li, X., & Sundquist, K. (2006) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2006.046615 · Cited by 16
Wong, P., Ho, W. Y., Yen, Y.-C., Sanford, E., & Ling, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.019 · Cited by 17
Disease onset in familial and sporadic primary progressive multiple sclerosis
Koch, M. W., Zhao, Y., Yee, I. M. L., Guimond, C., Kingwell, E., Rieckmann, P., Sadovnick, A. D., & Tremlett, H. L. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510367661 · Cited by 17
“All of these neurological conditions were considered sporadic diseases until the close study of patients with early-onset disease lead to the discovery of diseasemodifying genes such as SNCA (alpha-synuclein), SOD1 (superoxide dysmutase 1) and PSEN1 (Presenilin 1) (for review see Bertram and Tanzi).(17) The search for…”
BackgroundNew Perspectives for the Diagnosis of Alzheimers Disease
Urbanelli, L., Magini, A., Ciccarone, V. A., Trivelli, F., Polidoro, M., Tancini, B., & Emiliani, C. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909789104839 · Cited by 17
“Familial AD (FAD), representing less than 5% of the total [5], is an autosomal dominant disorder with onset before 65 years of age.”
BackgroundLeucine‐rich repeat kinase 2 and alternative splicing in Parkinson's disease
Elliott, D. A., Kim, W. S., Gorissen, S., Halliday, G. M., & Kwok, J. B. (2012) · Movement Disorders · doi:10.1002/mds.25005 · Cited by 18
“The disease is characterized clinically by a combination of motor symptoms, including tremor, bradykinesia, and rigidity.(1) Neuropathologically, the disease is characterized by severe loss of dopaminergic neu-”
BackgroundPiehl, F., & Olsson, T. P. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.031 · Cited by 18
Epigenetic Features Induced by Ischemia-Hypoxia in Cultured Rat Astrocytes
Yang, Q., Wu, X., Sun, J., Cui, J., & Li, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9027-8 · Cited by 16
Nursing Advocacy in a Postgenomic Age
Hamilton, R. (2009) · Nursing Clinics of North America · doi:10.1016/j.cnur.2009.07.007 · Cited by 16
“Alzheimer disease (AD).(27) An individual who simply wants to know if he or she is at risk for coronary artery disease (CAD) may not welcome information about risk for AD.”
BackgroundJayapalan, S., Subramanian, D., & Natarajan, J. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.004 · Cited by 17
“The use of linkage analysis and cloning techniques has led to the detection of genes involved in abundant Mendelian genetic disorders.(1,11) Protein kinases are the most common protein domains implicated in neurodegenerative diseases.”
BackgroundTreating Speech Movement Hypokinesia in Parkinson's Disease: Does Movement Size Matter?
Kearney, E., Haworth, B., Scholl, J., Faloutsos, P., Baljko, M., & Yunusova, Y. (2018) · Journal of Speech Language and Hearing Research · doi:10.1044/2018_jslhr-s-17-0439 · Cited by 17
Bipolar Spectrum disorders in Parkinson’s disease: a systematic evaluation
Bacciardi, S., Elefante, C., Brancati, G. E., Mazzucchi, S., Prete, E. D., Frosini, D., Maremmani, I., Lattanzi, L., Ceravolo, R., Bonuccelli, U., et al. (2020) · CNS Spectrums · doi:10.1017/s1092852920002126 · Cited by 17
Strategies to rescue mitochondria in Parkinson’s disease: The significance of mitochondrial transfer
Liang, J., Su, Z., Su, G., Rasheed, M., Tang, S., Sunniya, H., Maazouzi, M., Cui, Y., Wang, J., Wang, X., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102856 · Cited by 16
Mihoub, A. B., Acherar, S., Frochot, C., Malaplate, C., Yen, F. T., & Arab‐Tehrany, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063255 · Cited by 14
“Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases, as well as spinocerebellar ataxias, are common causes of cognitive impairment and morbidity in older adults [1,2].”
BackgroundLu, X., Lu, J., Li, S., Feng, S., Wang, Y., & Cui, L. (2024) · Aging and Disease · doi:10.14336/ad.2024.0209 · Cited by 20
Filipčík, P., Cente, M., Krajciova, G., Vanický, I., & Novák, M. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9372-8 · Cited by 14
“Tauopathies including Alzheimer’s disease (AD) represent one of the most serious health problems in the industrialized world (Bertram and Tanzi 2005).”
BackgroundGeng, J., Zhang, J., Yao, F., Liu, X., Liu, J., & Huang, Y. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01135-4 · Cited by 14
Moreno, J., Lanau, A. V., Madrigal, L., Pineda, A. Y. B., Hernandez, J. V., Campo, O., Soto-Ospina, A., Marín, P. A., Rishishwar, L., Norris, E. T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269955 · Cited by 15
Glycosylated clusterin species facilitate Aβ toxicity in human neurons
Foster, E. M., Fernandes, M., Dangla-Valls, A., Hublitz, P., Pangalos, M., Lovestone, S., Ribé, E. M., & Buckley, N. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-23167-z · Cited by 14
Whole genome expression profile in neuroblastoma cells exposed to 1-methyl-4-phenylpyridine
MAZZIO, E. A., & Soliman, K. F. A. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.06.009 · Cited by 16
“(Bertram and Tanzi, 2005, Hyun et al., 2005, Lesage and Brice, 2009, Mortiboys et al., 2010) One of the key pathological features of PD, involve damaged or dysfunctional mitochondria that contribute to bioenergetic crisis and subsequent neurodegeneration.”
BackgroundTesting the amyloid hypothesis of Alzheimer's disease in vivo
Gandy, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70055-7 · Cited by 16
Kakraba, S., Ayyadevara, S., Mainali, N., Balasubramaniam, M., Bowroju, S., Penthala, N. R., Atluri, R., Barger, S. W., Griffin, S. T., Crooks, P. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101498 · Cited by 11
Goyal, H., Sharma, A., Patel, C. D., Deepak, K. K., Tripathi, M., Gupta, P., Kumar, R., Bal, C. S., & Goyal, V. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02474-w · Cited by 13
Viral vectors as a promising nanotherapeutic approach against neurodegenerative disorders
Srivastava, V., Singh, A., Jain, G. K., Ahmad, F. J., Shukla, R., & Kesharwani, P. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.07.002 · Cited by 13
Paraquat Inhibits Autophagy Via Intensifying the Interaction Between HMGB1 and α-Synuclein
Wang, K., Zhang, B., Zhang, B., Wu, K., Tian, T., Yan, W., & Huang, M. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00490-x · Cited by 15
“2001; Bertram and Tanzi 2005), which is a typical progressive neurodegenerative disorder characterized by selective loss of dopaminergic neurons (Brichta and Greengard 2014; Mamelak 2018; Lou et al.”
BackgroundRed Light Treatment in an Axotomy Model of Neurodegeneration
Beirne, K., Rôżanowska, M., & Votruba, M. (2016) · Photochemistry and Photobiology · doi:10.1111/php.12606 · Cited by 13
“Alterations in dendritic morphology have also been found in Parkinson’s disease (51).”
BackgroundA Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment
Briones, M. R. S., Snyder, A. M., Ferreira, R. C., Neely, E. B., Connor, J. R., & Broach, J. R. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00039 · Cited by 14
“Amyotrophic lateral sclerosis (ALS), a motor neuron disease, is the third most prevalent neurodegenerative disease (4 cases per 100,000 people), being Alzheimer’s disease and Parkinson’s disease the first and second, respectively (1).”
BackgroundProgressive language impairments: Definitions, diagnoses, and prognoses
Croot, K. (2008) · Aphasiology · doi:10.1080/02687030801942981 · Cited by 15
“Frontier areas of research into progressive language impairments include pharmacological therapies (Burns & O’Brien, 2006; Huey, Putnam, & Grafman, 2006; McNeil et al., 1995; Reed, Johnson, Thompson, Weintraub, & Mesulam, 2004), early diagnostic indicators (Grossman et al., 2005) and genetics ( Bertram & Tanzi, 2005;…”
BackgroundMultifaceted role of oxidative stress in neurological disorders
Singh, A., Tiwari, V., & Roy, S. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10760-4 · Cited by 15
Mabrouk, O. S., Tichler, B., Arnold, H. M., Thoma, E. C., Alexanian, S. M., Chen, J., Liu, T.-Y., Hirschhorn, B., Llorens‐Arenas, R., Annand, J. W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04262-4 · Cited by 23
Sorraksa, N., Heebkaew, N., Promjantuek, W., Kunhorm, P., Kaokean, P., Chaicharoenaudomung, N., & Noisa, P. (2023) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2023.2258797 · Cited by 14
A multi‐layered network model identifies Akt1 as a common modulator of neurodegeneration
Na, D., Lim, D., Hong, J., Lee, H., Cho, D., Yu, M., Shaker, B., Ren, J. T., Lee, B., Song, J. G., et al. (2023) · Molecular Systems Biology · doi:10.15252/msb.202311801 · Cited by 15
“However, with the exception of diseases caused by CAG repeats (Gusella & MacDonald, 2006), familial forms with disease-causing mutations represent a small minority of all cases of a given ND type (Bertram & Tanzi, 2005).”
Agostini, F., Conti, M., Morone, G., Iudicelli, G., Fisicaro, A., Savina, A., Mangone, M., & Paoloni, M. (2024) · Brain Sciences · doi:10.3390/brainsci15010023 · Cited by 12
“Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world, characterized by bradykinesia, rigidity, tremor, and postural instability [1].”
Lee, G., Joo, J. C., Choi, B. Y., Lindroth, A. M., Park, S.-J., & Park, Y. J. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1205-y · Cited by 12
“generative disorder following Alzheimer’s disease, is mainly caused by progressive degeneration of dopaminergic neurons [1].”
BackgroundKorbolina, E. E., Александровна, Ж. А., Фурсова, А. Ж., Kozhevnikova, O. S., & Kolosova, N. G. (2016) · BMC Genetics · doi:10.1186/s12863-016-0461-7 · Cited by 12
Does Dementia Have a Microbial Cause?
Landry, R. L., & Embers, M. E. (2022) · NeuroSci · doi:10.3390/neurosci3020019 · Cited by 14
“These AD-causing mutations are characterized by primary alterations in amyloid metabolism, leading to an overabundance in the Aβ42 species, neuronal cell death, and dementia [30].”
BackgroundLack of association between PRNP 1368 polymorphism and Alzheimer's disease or vascular dementia
Jeong, B., Lee, K.-H., Lee, Y.-J., Kim, Y. J., Choi, E., Kim, Y.-H., Cho, Y.-S., Carp, R. I., & Kim, Y. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-32 · Cited by 13
Veerabathiran, R., Alphonsa, T., Akram Husain, R. S., Ahmed, S. S. S. J., Subramaniyan, K., & Kumar, S. S. (2016) · Meta Gene · doi:10.1016/j.mgene.2016.09.007 · Cited by 12
Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells
Wang, H., Tang, C., Jiang, Z., Zhou, X., Chen, J., Meng, N., Shen, H., & Lin, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4580 · Cited by 13
Yang, J. Y., Zhang, Y., ZHAO, S., ZHANG, Z., TONG, X., Wei, F., & Lu, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4027 · Cited by 13
“Parkinson's disease (PD) is one of the most common neuro-degenerative disorders (1), with prominent characteristics including the degradation of dopaminergic cells within the substantia nigra pars compacta (2), aberrant intracellular protein aggregation in the dorsal motor nucleus of the vagus, a…”
Association of DSC1, a gene modulated by adrenergic stimulation, with Alzheimer's disease
Ramos, M. C., Tenorio, R., Martínez-García, A., Sastre, I., Cuadrada, E. V., Frank, A., Rosich-Estragó, M., Valdivieso, F., & Bullido, M. J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.005 · Cited by 12
A phenotype for genetic studies of successful cognitive aging*
Silverman, J. M., Beeri, M. S., Grossman, H. T., Schmeidler, J., Wang, J. Y., & Lally, R. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30483 · Cited by 13
Sui, X., Prado, M. A., Paulo, J. A., Gygi, S. P., Finley, D. J., & Morimoto, R. I. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.28.509812 · Cited by 10
Unravelling the role of protein kinase R (PKR) in neurodegenerative disease: a review
Mohan, M., Mannan, A., & Singh, T. G. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10484-5 · Cited by 13
Kumar, S., Yadav, N., Pandey, S., & Thelma, B. K. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0953-5 · Cited by 11
Park, S., Park, S.-K., Watanabe, N., Hashimoto, T., Iwatsubo, T., Shelkovnikova, T. A., & Liebman, S. W. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008308 · Cited by 11
“Mutations in an increasing number of human genes have been found to cause familial neurodegenerative disease [1,2].”
BackgroundThe intersection between toxicology and aging research: A toxic aging coin perspective
Wise, J. P. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1014675 · Cited by 14
“Similar to aging, these neurodegenerative diseases are believed to have a significant environmental influence, with only 5–10% of cases linked to genetic mutations driving their etiology (Bertram and Tanzi, 2005; Philstrøm et al., 2018).”
BackgroundVasconcelos, C. F. M., Ribas, V. T., & Petrs‐Silva, H. (2023) · Cells · doi:10.3390/cells12172155 · Cited by 11
“Although all neurodegenerative diseases have significant genetic and inherited components, whose contribution in AD, PD and ALS is estimated to be 60–80% [69,70], ~40% [71], and ~60% [72], respectively, most cases exhibit a complex etiology, involving sporadic elements [66].”
BackgroundInfluentialComputer-aided discovery of dual-target compounds for Alzheimer’s from ayurvedic medicinal plants
Shah, M., Pervaiz, S., Ahmad, I., Ansari, S. H., de Paula, V. F., Ahmed, S., Khan, M. U., Fawy, K. F., Nishan, U., Dib, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325441 · Cited by 11
Choudhury, R., Ashtekar, H., Khot, K. B., Malngiang, M., Kumar, M. V., Mandal, S., & Das, B. (2023) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902023e21587 · Cited by 10
The thermodynamics of neurodegenerative disease
Meisl, G. (2024) · Biophysics Reviews · doi:10.1063/5.0180899 · Cited by 12
Álvarez, V., González, P., Corao, A. I., Menéndez‐González, M., Lahoz, C., Martínez, C., Calatayud, M., Morales, B., & Coto, E. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181572046 · Cited by 10
“AD is a complex and heterogeneous disease.(21) Some mutations in the APP, presenilin-1, and presenilin-2 genes cause rare and highly penetrant forms of early onset dominant-familial AD, but most of the cases exhibit a LOAD without a clear familial segregation.”
BackgroundProtein production is an early biomarker for RNA ‐targeted therapies
Self, W. K., Schoch, K. M., Alex, J., Barthélemy, N. R., Bollinger, J. G., Sato, C., Cole, T. A., Kordasiewicz, H. B., Swayze, E. E., Bateman, R. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.657 · Cited by 10
“1499 were performed over a 36-hour time period, as the halflife of amyloid beta peptide is ~9 h in CSF.18 To our knowledge, the results presented here are the first observations measuring new protein production of long-lived protein targets in the CNS after therapeutic intervention.”
MethodInfluentialPhysiological relevance of food antioxidants
Cömert, E. D., & Gökmen, V. (2020) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2020.03.002 · Cited by 14
Naj, A. C., Carney, R. M., Hahn, S. E., Slifer, M. A., Haines, J. L., & Pericak‐Vance, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00116-6 · Cited by 11
Einstellung zu genetischen Untersuchungen auf Alzheimer-Demenz
Illės, F., Bernhardt, T., Prell, K., Rietz, C., Rudinger, G., Frölich, L., Maier, W., & Rietschel, M. (2006) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-006-0377-3 · Cited by 11
Fine Mapping of Gene Regions Regulating Neurodegeneration
Swanberg, M., Harnesk, K., Ström, M., Diez, M., Lidman, O., & Piehl, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005906 · Cited by 11
“The common forms of these diseases often have a complex etiology, which includes a genetic component [12].”
BackgroundLi, C., Zhang, Y., Liang, J., Wu, C., & Zou, X. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.880105 · Cited by 9
“There is robust evidence that heavy metals can disturb neurotransmitter systems by multiple mechanisms, including the interaction with neurotransmitter receptors, the modification of certain gene and/or protein expression, and the collateral damage of their functions following Reactive Oxygen Species (ROS) production…”
BackgroundNiazi, S. K., & Magoola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12040851 · Cited by 7
“…causes underlying NDs associated with protein aggregation were uncovered, leading to the distinction between rarer familial forms, where disease-causing mutations are genetically inherited, and the more common sporadic forms, where genetic and environmental risk factors drive the pathogenesis [2].”
BackgroundChauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.